When K+ excretion is disrupted by CKD and/or RAAS inhibition, K+ may build up in the colon.
This causes the body to attempt to compensate with a marked increase in colonic secretion of K+
VELTASSA was designed to be fully ionized at the physiological pH of the colon for optimal ion exchange
Leveraging the body's natural compensatory mechanisms, VELTASSA binds K+ in exchange for calcium in the colon
VELTASSA is excreted with K+ to lower total body K+
CKD=chronic kidney disease; RAAS=renin-angiotensin-aldosterone system.
Sodium may cause issues for patients who cannot tolerate even a small increase in sodium load.
Based on radio-labeled drug-absorption studies, VELTASSA is not systemically absorbed.
VELTASSA is an off-white to light brown powder for oral suspension with free-flowing properties.
VELTASSA is indicated for the treatment of hyperkalemia.
Limitation of Use: VELTASSA should not be used as an emergency treatment for life‑threatening hyperkalemia because of its delayed onset of action.
Contraindications: VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.
Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post‑operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.
Hypomagnesemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.
Adverse Reactions: The most common adverse reactions (incidence ≥2%) are constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort and flatulence. Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.
Please see full Prescribing Information
The VELTASSA Prescribing Information has been updated to remove the Boxed WARNING for binding to other oral medications.
Administer VELTASSA at least 3 hours before or 3 hours after other oral medications. Please see Section 12.3 for detailed drug interactions.